New depression pill shows promise in early trial

NCT ID NCT06836063

Completed Symptom relief Sponsor: Suven Life Sciences Limited Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 2b trial tested whether ropanicant, an experimental drug taken twice daily, can reduce symptoms of major depressive disorder. 214 adults with moderate to severe depression received either ropanicant or a placebo for 6 weeks. The main goal was to see if the drug improved depression scores on a standard rating scale.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ropanicant (also known as SUVN-911)
What this could lead to: If successful, ropanicant could offer a new oral medication option for people with major depressive disorder.
What could go wrong: This is an early-phase (2b) trial with only 214 participants. The drug may not prove more effective than placebo, and side effects are still being evaluated.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MAJOR DEPRESSIVE DISORDER (MDD)

Contacts and locations

Locations

ATP Clinical Research

Orange, California, 92866, United States
Advanced Research Center, Inc.

Anaheim, California, 92805, United States
Atlanta Center for Medical Research

Atlanta, Georgia, 30331, United States
Behavioral Research Specialists, LLC

Glendale, California, 91206, United States
CenExcel iResearch LLC

Decatur, Georgia, 30030, United States
CenExcel iResearch LLC

Savannah, Georgia, 31405, United States
Center for Emotional Fitness

Cherry Hill, New Jersey, 08002, United States
Chicago Research Center Inc.

Chicago, Illinois, 60634, United States
Clinical Neuroscience Solutions Inc.

Memphis, Tennessee, 38119, United States
Clinical Neuroscience Solutions, Inc.

Jacksonville, Florida, 32256, United States
Clinical Neuroscience Solutions, Inc.

Orlando, Florida, 32801, United States
Collaborative Neuroscience Research

Torrance, California, 90504, United States
Community Clinical Research, Inc.

Austin, Texas, 78754, United States
Core Clinical Research

Everett, Washington, 98201, United States
Excell Research, Inc.

Oceanside, California, 92056, United States
Eximia Research-NC, LLC

Raleigh, North Carolina, 27607, United States
ForCare Clinical Research

Tampa, Florida, 33613, United States
Hassman Research Institue

Marlton, New Jersey, 08053, United States
Memorial Hermann Village

Houston, Texas, 77043, United States
Midwest Research Group

Saint Charles, Missouri, 63304, United States
Neurobehavioral Medicine Group

Bloomfield Hills, Michigan, 48302, United States
Neurobehavioral Research Inc.

Cedarhurst, New York, 11516, United States
North Texas Clinical Trials, LLC

Fort Worth, Texas, 76104, United States
Panhandle Research and Medical Clinic LLC

Pensacola, Florida, 32503, United States
Precise Research Centers

Flowood, Mississippi, 39232, United States
Premier Clinical Research Institute, Inc

Miami, Florida, 33122, United States
ProScience Research Group

Culver City, California, 90230, United States
Redbird Research, LLC

Las Vegas, Nevada, 89119, United States
Richmond Behavioral Associates

Staten Island, New York, 10312, United States
SPRI Clinical Trials, LLC

Brooklyn, New York, 11235, United States
Sooner Clinical Research, Inc

Oklahoma City, Oklahoma, 73116, United States
Synergy San Diego

Lemon Grove, California, 91945, United States
Vector Clinical Trials

Las Vegas, Nevada, 89128, United States
Woodland International Research Group LLC

Little Rock, Arkansas, 72211, United States
Woodland Research Northwest

Rogers, Arkansas, 72758, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.